Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by alleyesonmeon Aug 10, 2023 10:28pm
185 Views
Post# 35583116

Exciting times..

Exciting times..FDA site/API approval is a massive success for LABs and our global pharmaceutical partners im expecting NDA approval/505b news/details before year end...this FDA approval news is under appreciated because details are withheld for competitive reasons....canopy's asset light model has seen contracts outsourced for vapes, edibles and beverages but nothing YET for oils..I'm hopeful LABs is in the running and furthermore we will see other LPs following suit....considering canopy has shown major improvement on loss since adopting this "asset light" model and the financial state of the industry players, it's hard to imagine others won't follow suit, possibly bringing B2B revenue back from the dead...fact is I got the feeling..can't shake it....don't forget governmental review up Jan...excise tax/health Canada fees slashed?...how could it not?...1$per gram is ludacris...BULLISH...that's how I'm feeling anyways..
<< Previous
Bullboard Posts
Next >>